2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5282
    ApoA-I mimetic peptide 221882-20-8 98.90%
    ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) is an ApoA-I mimetic peptide. ApoA-I mimetic peptide has good phosphatidylcholine: cholesterol acyltransferase (LCAT) activation activity. ApoA-I mimetic peptide can be used to synthesize peptide/lipid complexes. ApoA-I mimetic peptide can be used in atherosclerosis research.
    ApoA-I mimetic peptide
  • HY-110273
    N106 862974-25-2 ≥98.0%
    N106 is a first-in-class sarcoplasmic reticulum calcium ATPase (SERCA2a) SUMOylation activator. N106 directly activates the SUMO-activating enzyme, E1 ligase. N106 can be used for heart failure research.
    N106
  • HY-117832
    Pyripyropene A 147444-03-9
    Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.
    Pyripyropene A
  • HY-125862
    Glutathione Reductase, baker's yeast 9001-48-3
    Glutathione reductase, baker's yeast (EC 1.6.4.2) is a reductase. Glutathione reductase, baker's yeast eliminates intracellular ROS. Glutathione reductase, baker's yeast reduces oxidized glutathione (GSSG) to reduced glutathione (GSH) using NADPH as an electron donor. Glutathione reductase, baker's yeast exerts antioxidant activity. Glutathione reductase is mainly used to study diseases associated with oxidative stress, such as Parkinson's disease and sickle cell anemia.
    Glutathione Reductase, baker's yeast
  • HY-148226
    20-5,14-HEDGE 1092380-14-7 99.28%
    20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE induces cell death in organotypic hippocampal slice cultures (OHSCs). 20-5,14-HEDGE enhances ROS production and reduces hypoxia-reoxygenation (HR)-induced apoptosis in ex vivo rat lung slices. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats. 20-5,14-HEDGE can be used for the study of pulmonary vascular signaling and lung injury-related research.
    20-5,14-HEDGE
  • HY-P1548A
    β-CGRP, human TFA 99.57%
    β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.
    β-CGRP, human TFA
  • HY-112868B
    ABH hydrochloride 194656-75-2
    ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis.
    ABH hydrochloride
  • HY-W010201
    Citronellol 106-22-9 98.40%
    Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis.
    Citronellol
  • HY-100447
    TM5275 sodium 1103926-82-4 98.97%
    TM5275 sodium is a plasminogen activator inhibitor (PAI-1) with an IC50 of 6.95 μM.
    TM5275 sodium
  • HY-100828
    BGP-15 66611-37-8 98.0%
    BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively.
    BGP-15
  • HY-101419
    CYM-5541 945128-26-7 99.65%
    CYM-5541 (ML249) is an selective and allosteric S1P3 receptor agonist with an EC50 between 72 and 132 nM.
    CYM-5541
  • HY-12542A
    Dantrolene sodium hemiheptahydrate 24868-20-0 99.79%
    Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is also a calcium channel protein inhibitor. Dantrolene sodium hemiheptahydrate inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium hemiheptahydrate offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties.
    Dantrolene sodium hemiheptahydrate
  • HY-14806A
    Teneligliptin hydrobromide 906093-29-6 ≥99.0%
    Teneligliptin (MP-513) hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus.
    Teneligliptin hydrobromide
  • HY-13575
    Blonanserin 132810-10-7 99.62%
    Blonanserin (AD-5423) is a potent and orally active 5-HT2A (Ki=0.812 nM) and dopamine D2 receptor (Ki =0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension.
    Blonanserin
  • HY-125079
    DSP-2230 1233231-30-5 98.33%
    DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC50s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain.
    DSP-2230
  • HY-B0358A
    Flunarizine dihydrochloride 30484-77-6 99.36%
    Flunarizine dihydrochloride is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
    Flunarizine dihydrochloride
  • HY-17005
    Olmesartan medoxomil 144689-63-4 99.12%
    Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil
  • HY-17401
    Ranolazine dihydrochloride 95635-56-6 99.99%
    Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor.
    Ranolazine dihydrochloride
  • HY-21065
    Tienilic acid 40180-04-9
    Tienilic acid (Ticrynafen; ANP 3624) acts as a diuretic hypotensive agent. However, Tienilic acid induces hepatotoxicity. Tienilic acid is converted into electrophilic metabolites by cytochrome P450 (CYP) in vitro.
    Tienilic acid
  • HY-B0800
    Guanethidine sulfate 645-43-2 ≥98.0%
    Guanethidine sulfate (Guanethidine monosulfate), an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sulfate enters noradrenergic nerve terminals by the neuronal amine carrier.
    Guanethidine sulfate
Cat. No. Product Name / Synonyms Application Reactivity